Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  2013-02-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2012.43.0652PMID 23401448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonsmall cell lung cancer

  2013cited by this paper
• Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

  2012cited by this paper
• Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.

  2012cited by this paper
• Characterization of serum proteome in patients with metastatic colorectal cancer responsive and nonresponsive to bevacizumab using 2 d-DIGE.

  2012cited by this paper
• Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

  2012cited by this paper
• Cytologic and molecular characterizations of CTC detected in patients with metastatic colorectal carcinomas.

  2012cited by this paper
• First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

  2012influential reference
• Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.

  2012cited by this paper
• Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis.

  2012cited by this paper
• LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

  2012cited by this paper
• A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011influential reference
• Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor

  2011cited by this paper
• Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

  2011cited by this paper
• 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

  2011cited by this paper
• Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.

  2011cited by this paper
• Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer.

  2011cited by this paper
• Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

  2010cited by this paper
• EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

  2010cited by this paper
• Non-small cell lung cancer.

  2010cited by this paper
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.

  2010cited by this paper
• responding The

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?

  2010cited by this paper
• Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

  2010cited by this paper
• Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

  2010cited by this paper
• Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010influential reference
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.

  2009cited by this paper
• Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

  2009cited by this paper
• F1000 highlights

  2009influential reference
• Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

  2009cited by this paper
• First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

  2009cited by this paper
• Phase II randomized trial of erlotinib versus vinorelbine in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) aged ≥70 years in Taiwan.

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first

  2008cited by this paper
• Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

  2008cited by this paper
• Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

  2008cited by this paper
• Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

  2008cited by this paper
• Response of intracranial metastases to erlotinib therapy.

  2007cited by this paper
• Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases

  2007cited by this paper
• CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation

  2007cited by this paper
• Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).

  2006cited by this paper
• Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

  2006cited by this paper
• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

  2006cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

  2005cited by this paper
• Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

  2005cited by this paper
• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

  2005cited by this paper
• Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

  2005influential reference
• Brain Metastasis Responding to Gefitinib Alone

  2004cited by this paper
• Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

  2003cited by this paper
• Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1.

  2001cited by this paper
• Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.

  1999cited by this paper

• Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.

  2026cites this paper
• Assessing the prognosis of metastatic or recurrent non-small cell lung cancer in the era of modern systemic therapies: a multivariable analysis of 343 patients treated in Poland

  2025cites this paper
• Efficacy and safety of Toliparibumab for the treatment of non-small cell lung cancer: a systematic review and meta-analysis

  2024cites this paper
• Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile

  2024cites this paper
• Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%

  2023cites this paper
• Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases

  2021cites this paper
• Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study

  2021cites this paper
• Эффективность интегрированной химиотерапии с ингибиторами тирозинкиназы рецептора EGFR у пациентов с немелкоклеточным раком легкого и активирующей мутацией гена EGFR.

  2021cites this paper
• Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer

  2021cites this paper
• Brazilian Women With Lung Cancer Have a Higher Overall Survival Than Their Male Equivalents: A Cohort Study.

  2020cites this paper
• ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.

  2020cites this paper
• Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis

  2020cites this paper
• Properties of FDA-approved small molecule protein kinase inhibitors.

  2019cites this paper
• Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma.

  2019cites this paper
• Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.

  2019cites this paper
• The efficacy of the ALK inhibitor crizotinib as compared with standard chemo- therapy as first-line treatment for advanced ALK-positive non–small-cell lung can-

  2019cites this paper
• Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.

  2019cites this paper
• Long non-coding RNA LOC554202 promotes acquired gefitinib resistance in non-small cell lung cancer through upregulating miR-31 expression

  2019cites this paper
• Astragalus polysaccharides (PG2) Enhances the M1 Polarization of Macrophages, Functional Maturation of Dendritic Cells, and T Cell-Mediated Anticancer Immune Responses in Patients with Lung Cancer

  2019cites this paper
• Polymeric Micelles in Management of Lung Cancer

  2019cites this paper
• Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma

  2019cites this paper
• Exhaustive Review on Lung Cancers: Novel Technologies.

  2019cites this paper
• Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives

  2018cites this paper
• AKCİĞER ADENOKARSİNOMUNDA TÜMÖR BOYUTU VE HİSTOPATOLOJİK ALT TİPİN SAĞKALIM ÜZERİNE ETKİLERİ

  2018cites this paper
• Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis

  2018cites this paper
• Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.

  2018cites this paper
• Tyrosine kinase inhibitor‐induced IL‐6/STAT3 activation decreases sensitivity of EGFR‐mutant non‐small cell lung cancer to icotinib

  2018cites this paper
• Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

  2018cites this paper
• Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells

  2018cites this paper
• Efficacy and safety of crizotinib for treatment of ALK-positive NSCLC : a meta-analysis

  2018cites this paper
• The antiangiogenic action of cisplatin on endothelial cells is mediated through the release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells

  2018cites this paper
• Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation

  2017cites this paper
• Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma

  2017cites this paper
• Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

  2017cites this paper
• Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

  2017cites this paper
• Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

  2017cites this paper
• Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)

  2017cites this paper
• Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

  2017cites this paper
• Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms

  2017cites this paper
• Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

  2017cites this paper
• Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer

  2017cites this paper
• Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice

  2017cites this paper
• Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

  2017cites this paper
• University of Groningen Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer , a review of the literature

  2017cites this paper
• The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer

  2017cites this paper
• Development and validation of a radiomics nomogram for progression-free survival prediction in stage IV EGFR-mutant non-small cell lung cancer

  2017cites this paper
• Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis

  2017influential citation
• Resistance mechanisms in lung cancer patients with EGFR or ALK aberrations treated with kinase inhibitors

  2017cites this paper
• Gefitinib: an “orphan” drug for non-small cell lung cancer

  2017cites this paper
• The treatment of patients with advanced lung cancer associated with EGFR mutation

  2017cites this paper
• The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations

  2016cites this paper
• The Clinical Strategy to Overcome EGFR-TKI Acquired Resistance for NSCLC Patients

  2016cites this paper
• Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

  2016cites this paper
• EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

  2016cites this paper
• Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI)

  2016cites this paper
• Current Challenges in Cancer Treatment.

  2016cites this paper
• Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors.

  2016cites this paper
• Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.

  2016cites this paper
• Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

  2016cites this paper
• Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

  2016cites this paper
• Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations

  2016influential citation
• TEYSUNO™ (S-1) IS BENEFICIAL FOR EGFR-TKI REFRACTORY NSCLC PATIENTS

  2016cites this paper
• Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation

  2016cites this paper
• Knockdown of HNRNPA1 inhibits lung adenocarcinoma cell proliferation through cell cycle arrest at G0/G1 phase.

  2016cites this paper
• Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer

  2015cites this paper
• Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.

  2015influential citation
• Non-small-cell lung cancer

  2015cites this paper
• PCR-sequencing is a complementary method to amplification refractory mutation system for EGFR gene mutation analysis in FFPE samples.

  2015cites this paper
• Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

  2015cites this paper
• Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review.

  2015cites this paper
• Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma

  2015cites this paper
• Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

  2015cites this paper
• Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

  2015cites this paper
• Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.

  2015cites this paper
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

  2015cites this paper
• Refining the treatment of NSCLC according to histological and molecular subtypes

  2015cites this paper
• Annotation of Sequence Variants in Cancer Samples: Processes and Pitfalls for Routine Assays in the Clinical Laboratory.

  2015cites this paper
• Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer

  2015cites this paper
• Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis

  2015cites this paper
• Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

  2014cites this paper
• Efficacy and predictors of EGFR tyrosine kinase inhibitors in Chinese advanced lung adenocarcinoma: analyses of 253 cases from a single institute.

  2014cites this paper
• The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

  2014cites this paper
• Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.

  2014cites this paper
• Ignore molecular oncology at your peril.

  2014cites this paper
• miRNAs and Target Genes in Breast Cancer Metastasis

  2014cites this paper
• Targeting epidermal growth factor receptor in the management of lung cancer.

  2014cites this paper
• Stereotaktische Strahlentherapie von Metastasen

  2014cites this paper
• Clinical Perspectives: Breast Cancer Brain Metastasis

  2014cites this paper
• The Value of Targeted Therapies in Lung Cancer

  2014cites this paper
• Personalized treatment options in Non-small Cell Lung Cancer

  2014cites this paper
• The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma.

  2014cites this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cites this paper
• EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer

  2014cites this paper
• Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

  2014cites this paper
• Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice.

  2014cites this paper
• Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

  2014cites this paper
• Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials

  2014cites this paper
• Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer.

  2014cites this paper
• O potencial papel da cinase reguladora extracelular (ERK) na sobrevida de pacientes com adenocarcinoma de pulmão em estágios iniciais

  2013cites this paper
• Mutation de l’EGFR, de l’étude du gène à la pratique clinique : exemplarité ou exception ?

  2013cites this paper